A Phase 3 interventional study of Aripiprazole in Tourette's Disorder and Tic Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 33 sites in 4 countries. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2015-10-16.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.
Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 3, and was the 7th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 7 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2013.
This study's enrollment of 110 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 97 across the 10 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 9 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing aripiprazole in Tourette Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
Tourette's Disorder is a neuropsychiatric condition that is characterized by the appearance of tics that can be simple or complex in nature. A tic is a sudden, rapid, recurrent, non-rhythmic, stereotyped motor movement or vocalization. There are a very limited number of medications approved for the treatment of Tourette's Disorder. The goal of the current trial is to obtain additional efficacy, safety, and tolerability data in a controlled condition of a Once-daily aripiprazole formulation in children and adolescents with Tourette's Disorder. The trial is a 52-week extension to the double-blind trial.
The Once-daily tablet formulation that will be evaluated in this trial represents a daily dosage regimen that is intended to be administered to children and adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole Immediate Release Once-Daily
Drug: Aripiprazole
Open Label: Once-Daily formulation of aripiprazole flex dose regimine
Also known as: Abilify
Percentage of Participants With Adverse Events.
An AE is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the study drug. A treatment emergent adverse event (TEAE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to have a causal relationship with the study drug. Serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolonged hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
Time frame: Baseline, throighout the 52-week treatmetn and 30±3 days after last trial visit
Percentage of Participants With Clinically Significant Abnormal Laboratory Test Results.
Laboratory tests including hematology, serum chemistry, and urinalysis were performed for all the participants. The central laboratory was used for all laboratory testing whenever possible. Any value outside the normal range was flagged for the attention of the study physician who was to indicate whether the value was clinically significant based on the pre-defined criteria for identifying laboratory values of potential clinical relevance. Percentage of participants noted with abnormal laboratory values are reported below.
Time frame: Baseline to Week 52
Percentage of Participants With Clinically Significant Abnormal Vital Signs.
Vital sign measurements included systolic and diastolic blood pressure (BP) and heart rate, which were performed at all clinic visits. Criteria for identifying vital signs of potential clinical relevance included: Heart rate: ≥ 15 beats per minute (bpm) increase/decrease from Baseline (final visit of study 31-12-293); Systolic BP: ≥ 20 mmHg increase/decrease from Baseline; Diastolic BP: ≥ 15mmHg increase/decrease from Baseline; Orthostatic hypotension: ≥ 20 mmHg decrease in systolic BP and a ≥ 25 bpm increase in heart rate from supine to sitting/standing. Percentage of participants noted with abnormal vital sign measurements are reported below.
Time frame: Baseline to Week 52
Percentage of Participants With Clinically Significant Abnormal Electrocardiogram (ECG).
Three 12-lead ECGs (scheduled 5 minutes apart) were recorded. Some of the pre-defined criteria for identifying ECG measurements of potential clinical relevance included: Tachycardia/sinus tachycardia: increase of ≥15 bpm from Baseline; increase in QTc of ≥10% from Baseline. The other abnormalities not present at Baseline and were present during the time of measurement were recorded. Percentage of participants noted with abnormal ECG findings are reported below.
Time frame: Baseline to Week 52
Mean Change From Baseline in Body Weight.
Criteria for identifying weight of potential clinical relevance was: ≥ 7% kilogram increase/decrease from Baseline (Final visit of Trial 31-12-293).
Time frame: Baseline to Weeks 12, 28, 36, 44, 52/Last visit.
Mean Change From Baseline in Body Mass Index (BMI).
BMI was calculated at the Baseline visit (using the Baseline height from study 31-12-293) and at Weeks 28 and 52/ET where height measured at baseline in the current trial was used to calculate BMI.
Time frame: Baseline to Weeks 28, 52 and Last visit.
Mean Change From Baseline in Waist Circumference.
Waist circumference was measured at Baseline, Weeks 12, 28, 36, 44, and the Week 52/last visit in centimeters.
Time frame: Baseline to Weeks 12, 28, 36, 44, and 52/last visit.
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score.
The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest, and the investigator also made global judgments on the participant's dyskinesias (items 8 through 10). Each item was rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness/severe distress). In addition, the AIMS included 2 yes/no questions that addressed the subject's dental status (since an edentulous state can cause lingual dyskinesias). The AIMS movement rating score (range 0 to 28) was the sum of the rating scores for facial and oral moments (ie, items 1 to 4), extremity movements (ie, items 5 and 6), and trunk movements (ie, item 7).
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Simpson-Angus Scale (SAS) Total Score.
The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item was rated on a 5-point scale, with a score of 1 representing absence of symptoms, and a score of 5 representing a severe condition. The SAS total score (range 10 to 50) was the sum of the rating scores for 10 items from the SAS panel.
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Total Score.
The BARS Global Score is derived from the global clinical evaluation of akathisia on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia.
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Suicidal Ideation Intensity Total Score Based on Columbia-Suicide Severity Rating Scale (C-SSRS).
The C-SSRS consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post baseline/"since last visit" evaluation that focuses on suicidality since the last trial visit. The C-SSRS data at Baseline and post baseline were summarized for incidence of reporting: Suicidality, Suicidal behavior (and its 4 types), Suicidal ideation (and its 5 types). The intensity score of each item ranges from 1 (least severe) to 5 (most severe), which leads to the range of the total score from 0 to 25.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Average Score of Attention Deficit Disorder/Attention-deficit Hyperactivity Disorder (ADD/ADHD) of Swanson, Nolan, and Pelham-IV Rating Scale (SNAP-IV).
The SNAP-IV Rating Scale is a revision of the SNAP Questionnaire. The SNAP-IV assesses inattention and hyperactivity/impulsivity, as well as oppositional defiant disorder that are often present in children with ADD/ADHD. The SNAP-IV was administered as a semi-structured interview with the participant and caregiver. The SNAP-IV is based on a 0 to 3 rating scale: not at all = 0, just a little = 1, quite a bit = 2, and very much = 3. The ADD/ADHD subscale includes items 1 through 19 (items 1-9 measure inattention, items 11-19 measure hyperactivity/ impulsivity, and item 10 for inattention domain), items 4, 8, 11, 31, and 32 measure inattention/overactivity, and items 21, 23, 29, 34, and 35 measure aggression/defiance. Items 4, 8, 11, 21, 32, 33, 36, 37, 38, and 39 form the Conners Index. Subscale average scores on the SNAP IV were calculated by summing the scores on the items in the subset and dividing by the number of items in the subset.
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS).
The CY-BOCS is a semi-structured interview used with children and adolescents aged 6 to 17 years to rate the severity and type of symptoms in participants with obsessive compulsive disorder. In general, the items depend on the participant's report; however, the final rating is based on the clinical judgment of the interviewer and should include additional information supplied by others. Nineteen items are rated in the CY-BOCS, but only items 1 through 10 (excluding items lb and 6b) are used to determine the total score. The total CY-BOCS score is the sum of items 1 through 10 (excluding lb and 6b), whereas the obsession and compulsion subtotals are the sums of items 1 through 5 (excluding lb) and 6 through 10 (excluding 6b), respectively. CY-BOCS total score could range from 0 to 40, and the obsession and compulsion subscale total scores could each range from 0 to 20. Higher scores indicate worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Children's Depression Rating Scale - Revised (CDRS-R).
The CDRS-R is a brief rating scale based on a semi-structured interview with the child and an adult informant who knows the child well. Designed for 6- to 12-year-old children, and successfully used with adolescents, it can be administered in 15 to 20 minutes. The interviewer rates 17 symptom areas (including those that serve as Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision criteria for a diagnosis of depression): impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome.
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline in Pediatric Anxiety Rating Scale (PARS).
The PARS is used to rate the severity of anxiety in children and adolescents, aged 6 to 17 years. The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score was the sum of items 2, 3, 5, 6, and 7. The total severity score ranged from 0 (no anxiety) to 25 (worst anxiety).
Time frame: Baseline, Weeks 4, 8, 12, 20, 28, 36, 44, 52, and Last visit
Change From Baseline to Endpoint on the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS).
The YGTSS is a semi-structured clinical interview which consists of a tic inventory, with 5 separate ratings to assess the number, intensity, frequency, complexity and interference of tics, plus an overall impairment/disability score. Ratings are made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics each, including number, frequency, intensity, complexity, and interference. Summation of these 10 scores (ie, 0-50) provides a TTS that was the secondary outcome measure in this trial. The YGTSS ranking of impairment, with a maximum of 50 points, is based on the impact of the tic disorder on areas of self-esteem, family life, social acceptance, and school scores. The total severity score ranged from 0 (no impairment) to 50 (worst impairment).
Time frame: Baseline to Week 52
Mean Clinical Global Impressions for Tourette's Syndrome (CGI-TS) Change Score at Endpoint.
The CGI is a 7-point Likert scale used in a multitude of clinical trials as a clinical global measure to assess the severity and change in disease symptomatology (ie, tics). The CGI was included as a secondary scale to provide a more complete assessment of clinical efficacy. To assess CGI-TS severity, the rater or investigator will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" However, the evaluation of illness will be limited to manifestations of Tourette's Disorder only. Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.
Time frame: Baseline to Week 52
Change From Baseline to Endpoint in CGI-TS Severity of Illness Score.
The final CGI-TS score was compared to the participant's baseline condition at the time of entry into the open-label study, rather than the CGI-TS baseline condition at the time participants enrolled into the preceding study. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Baseline to Week 52
Mean Change From Baseline to Endpoint in Total YGTSS Score.
The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) for motor and vocal tics, and an impairment ranking. The YGTSS TTS is the summation of the severity scores of motor and vocal tics (range of 0 \[no impairment\] to 50 \[maximum impairment\]). The total YGTSS score is the summation of the severity scores of motor and vocal tics and the ranking of impairment (total range of 0 \[no impairment\] to 100 \[maximum impairment\]).
Time frame: Baseline to Week 52
Percentage of Participants With Response (Response Rate).
Clinical response was defined as \> 25% improvement from Baseline to endpoint in YGTSS TTS or a CGI-TS change score of 1 (very much improved) or 2 (much improved) at endpoint.
Time frame: Weeks 4, 8, 12, 20, 28, 36, 44 and 52
Percentage of Participants With Treatment Discontinuation (Treatment Discontinuation Rate).
The treatment discontinuation rate was calculated as the number of discontinued participants (ie, those withdrawn from the study without completing the Week 52 visit) divided by the number of all enrolled participants.
Time frame: Baseline to Week 52
The trial was conducted in 110 participants at 37 trials sites in 4 countries. Participants who were aged 7 to 17 years at screening or who turned 18 years during their participation in Trial 31-12-293 (NCT01727700) were enrolled in this extension trial
| Milestone | Open-label Aripiprazole |
|---|---|
| Started | 110 |
| Completed | 75 |
| Not completed | 35 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Adverse event | 10 |
| Withdrew: Participant met withdrawal criteria | 5 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Protocol deviation | 2 |
An AE is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the study drug. A treatment emergent adverse event (TEAE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not considered related to have a causal relationship with the study drug. Serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolonged hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
| Percentage of participants | Open-label Aripiprazole |
|---|---|
| Participants with TEAEs | 76.4 |
| Participants with severe TEAEs | 4.5 |
| Participants with serious TEAEs | 3.6 |
Laboratory tests including hematology, serum chemistry, and urinalysis were performed for all the participants. The central laboratory was used for all laboratory testing whenever possible. Any value outside the normal range was flagged for the attention of the study physician who was to indicate whether the value was clinically significant based on the pre-defined criteria for identifying laboratory values of potential clinical relevance. Percentage of participants noted with abnormal laboratory values are reported below.
| Percentage of participants | Open-label Aripiprazole |
|---|---|
| Eosinophils (high) (N=108) | 3.7 |
| Hemoglobin A1C (high) (N=107) | 0.9 |
| Absolute neutrophils (low) (N=108) | 13.0 |
| White blood count (low) (N=108) | 4.6 |
| Total bilirubin (high) (N=108) | 1.9 |
| Creatine phosphokinase (high) (N=108) | 0.9 |
| Fasting glucose (high) (N=93) | 3.2 |
| LDL cholesterol (high) (N=92) | 3.3 |
| Triglycerides (high) (N=92) | 17.4 |
| Uric acid (high) (N=108) | 0.9 |
| Potassium (high) (N=108) | 0.9 |
| Urine glucose (high) (N=104) | 1.0 |
| Urine protein (high) (N=104) | 1.9 |
| Prolactin (high) (N=104) | 3.8 |
Vital sign measurements included systolic and diastolic blood pressure (BP) and heart rate, which were performed at all clinic visits. Criteria for identifying vital signs of potential clinical relevance included: Heart rate: ≥ 15 beats per minute (bpm) increase/decrease from Baseline (final visit of study 31-12-293); Systolic BP: ≥ 20 mmHg increase/decrease from Baseline; Diastolic BP: ≥ 15mmHg increase/decrease from Baseline; Orthostatic hypotension: ≥ 20 mmHg decrease in systolic BP and a ≥ 25 bpm increase in heart rate from supine to sitting/standing. Percentage of participants noted with abnormal vital sign measurements are reported below.
| Percentage of participants | Open-label Aripiprazole |
|---|---|
| Heart rate-Supine (increase) (N=108) | 0.9 |
| Heart rate-Supine (decrease) (N=108) | 0.9 |
| Heart rate-Standing (increase) (N=108) | 9.3 |
| Systolic Supine BP (decrease) (N=108) | 6.5 |
| Systolic Standing BP (decrease) (N=108) | 3.7 |
| Diastolic Supine BP (decrease) (N=108) | 0.9 |
| Diastolic Standing BP (decrease) (N=108) | 5.6 |
| Orthostatic hypotension (N=110) | 2.7 |
Three 12-lead ECGs (scheduled 5 minutes apart) were recorded. Some of the pre-defined criteria for identifying ECG measurements of potential clinical relevance included: Tachycardia/sinus tachycardia: increase of ≥15 bpm from Baseline; increase in QTc of ≥10% from Baseline. The other abnormalities not present at Baseline and were present during the time of measurement were recorded. Percentage of participants noted with abnormal ECG findings are reported below.
| Percentage of participants | Open-label Aripiprazole |
|---|---|
| Tachycardia (N=106) | 0.9 |
| Sinus Tachycardia (N=106) | 0.9 |
| Supraventricular premature beat (N=106) | 1.9 |
| Ventricular premature beat (N=106) | 0.9 |
| Right bundle branch block (N=106) | 1.9 |
| QTcB (N=106) | 0.9 |
| QTcN (N=106) | 0.9 |
Criteria for identifying weight of potential clinical relevance was: ≥ 7% kilogram increase/decrease from Baseline (Final visit of Trial 31-12-293).
| Kilogram | Open-label Aripiprazole |
|---|---|
| Week 12 (N=102) | 1.8 ± 2.3 |
| Week 28 (N=90) | 4.8 ± 3.8 |
| Week 36 (N=88) | 5.8 ± 4.4 |
| Week 44 (N=81) | 6.8 ± 5.3 |
| Week 52 (N=77) | 8.0 ± 5.4 |
| Last visit (N=106) | 7.2 ± 5.8 |
BMI was calculated at the Baseline visit (using the Baseline height from study 31-12-293) and at Weeks 28 and 52/ET where height measured at baseline in the current trial was used to calculate BMI.
| Kg/M^2 | Open-label Aripiprazole |
|---|---|
| Week 28 (N=90) | 3.3 ± 16.2 |
| Week 52 (N=77) | 1.9 ± 2.3 |
| Last visit (N=106) | 1.8 ± 2.3 |
Waist circumference was measured at Baseline, Weeks 12, 28, 36, 44, and the Week 52/last visit in centimeters.
| Centimeter | Open-label Aripiprazole |
|---|---|
| Week 12 (N=102) | 2.2 ± 8.3 |
| Week 28 (N=90) | 3.7 ± 9.7 |
| Week 36 (N=87) | 3.5 ± 6.5 |
| Week 44 (N=80) | 4.5 ± 6.7 |
| Week 52 (N=75) | 5.5 ± 6.5 |
| Last visit (N=106) | 4.6 ± 6.4 |
The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest, and the investigator also made global judgments on the participant's dyskinesias (items 8 through 10). Each item was rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness/severe distress). In addition, the AIMS included 2 yes/no questions that addressed the subject's dental status (since an edentulous state can cause lingual dyskinesias). The AIMS movement rating score (range 0 to 28) was the sum of the rating scores for facial and oral moments (ie, items 1 to 4), extremity movements (ie, items 5 and 6), and trunk movements (ie, item 7).
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | -1.0 ± 3.0 |
| Week 8 (N=105) | -1.3 ± 3.4 |
| Week 12 (N=104) | -1.7 ± 3.7 |
| Week 20 (N=100) | -1.8 ± 3.9 |
| Week 28 (N=92) | -2.0 ± 4.3 |
| Week 36 (N=88) | -2.2 ± 4.5 |
| Week 44 (N=82) | -2.3 ± 4.6 |
| Week 52 (N=77) | -2.3 ± 4.7 |
| Last vist (N=109) | -1.8 ± 4.3 |
The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item was rated on a 5-point scale, with a score of 1 representing absence of symptoms, and a score of 5 representing a severe condition. The SAS total score (range 10 to 50) was the sum of the rating scores for 10 items from the SAS panel.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | 0.0 ± 0.9 |
| Week 8 (N=104) | -0.0 ± 0.9 |
| Week 12 (N=104) | -0.0 ± 0.9 |
| Week 20 (N=100) | -0.1 ± 0.7 |
| Week 28 (N=92) | -0.2 ± 0.8 |
| Week 36 (N=88) | -0.2 ± 0.8 |
| Week 44 (N=82) | -0.2 ± 0.8 |
| Week 52 (N=77) | -0.1 ± 0.8 |
| Last vist (N=109) | -0.1 ± 0.7 |
The BARS Global Score is derived from the global clinical evaluation of akathisia on a 6-point scale, with 0 representing absence of symptoms and a score of 5 representing severe akathisia.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | 0.0 ± 0.4 |
| Week 8 (N=105) | 0.0 ± 0.4 |
| Week 12 (N=104) | -0.0 ± 0.3 |
| Week 20 (N=100) | -0.1 ± 0.3 |
| Week 28 (N=92) | -0.1 ± 0.3 |
| Week 36 (N=88) | -0.1 ± 0.3 |
| Week 44 (N=82) | -0.1 ± 0.3 |
| Week 52 (N=77) | -0.1 ± 0.3 |
| Last vist (N=109) | -0.0 ± 0.3 |
The C-SSRS consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post baseline/"since last visit" evaluation that focuses on suicidality since the last trial visit. The C-SSRS data at Baseline and post baseline were summarized for incidence of reporting: Suicidality, Suicidal behavior (and its 4 types), Suicidal ideation (and its 5 types). The intensity score of each item ranges from 1 (least severe) to 5 (most severe), which leads to the range of the total score from 0 to 25.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 1 (N=108) | -0.1 ± 0.7 |
| Week 2 (N=106) | -0.0 ± 0.5 |
| Week 4 (N=107) | 0.0 ± 0.8 |
| Week 8 (N=105) | -0.1 ± 0.8 |
| Week 12 (N=104) | -0.0 ± 0.5 |
| Week 20 (N=100) | -0.1 ± 0.5 |
| Week 28 (N=92) | 0.1 ± 1.0 |
| Week 36 (N=88) | 0.1 ± 1.3 |
| Week 44 (N=82) | 0.0 ± 0.0 |
| Week 52 (N=77) | 0.2 ± 1.3 |
| Last vist (N=110) | 0.0 ± 1.3 |
The SNAP-IV Rating Scale is a revision of the SNAP Questionnaire. The SNAP-IV assesses inattention and hyperactivity/impulsivity, as well as oppositional defiant disorder that are often present in children with ADD/ADHD. The SNAP-IV was administered as a semi-structured interview with the participant and caregiver. The SNAP-IV is based on a 0 to 3 rating scale: not at all = 0, just a little = 1, quite a bit = 2, and very much = 3. The ADD/ADHD subscale includes items 1 through 19 (items 1-9 measure inattention, items 11-19 measure hyperactivity/ impulsivity, and item 10 for inattention domain), items 4, 8, 11, 31, and 32 measure inattention/overactivity, and items 21, 23, 29, 34, and 35 measure aggression/defiance. Items 4, 8, 11, 21, 32, 33, 36, 37, 38, and 39 form the Conners Index. Subscale average scores on the SNAP IV were calculated by summing the scores on the items in the subset and dividing by the number of items in the subset.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | -0.2 ± 0.4 |
| Week 8 (N=105) | -0.2 ± 0.4 |
| Week 12 (N=104) | -0.3 ± 0.4 |
| Week 20 (N=100) | -0.2 ± 0.4 |
| Week 28 (N=92) | -0.2 ± 0.4 |
| Week 36 (N=88) | -0.2 ± 0.4 |
| Week 44 (N=82) | -0.2 ± 0.4 |
| Week 52 (N=77) | -0.2 ± 0.4 |
| Last vist (N=109) | -0.2 ± 0.5 |
The CY-BOCS is a semi-structured interview used with children and adolescents aged 6 to 17 years to rate the severity and type of symptoms in participants with obsessive compulsive disorder. In general, the items depend on the participant's report; however, the final rating is based on the clinical judgment of the interviewer and should include additional information supplied by others. Nineteen items are rated in the CY-BOCS, but only items 1 through 10 (excluding items lb and 6b) are used to determine the total score. The total CY-BOCS score is the sum of items 1 through 10 (excluding lb and 6b), whereas the obsession and compulsion subtotals are the sums of items 1 through 5 (excluding lb) and 6 through 10 (excluding 6b), respectively. CY-BOCS total score could range from 0 to 40, and the obsession and compulsion subscale total scores could each range from 0 to 20. Higher scores indicate worse outcome.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | -0.2 ± 2.6 |
| Week 8 (N=105) | -0.1 ± 3.0 |
| Week 12 (N=104) | -0.5 ± 2.7 |
| Week 20 (N=100) | -0.6 ± 3.0 |
| Week 28 (N=92) | -0.5 ± 3.3 |
| Week 36 (N=88) | -0.7 ± 3.4 |
| Week 44 (N=82) | -0.8 ± 3.7 |
| Week 52 (N=77) | -0.9 ± 3.9 |
| Last vist (N=109) | -0.7 ± 3.4 |
The CDRS-R is a brief rating scale based on a semi-structured interview with the child and an adult informant who knows the child well. Designed for 6- to 12-year-old children, and successfully used with adolescents, it can be administered in 15 to 20 minutes. The interviewer rates 17 symptom areas (including those that serve as Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision criteria for a diagnosis of depression): impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=104) | -0.4 ± 4.4 |
| Week 8 (N=100) | -0.4 ± 3.8 |
| Week 12 (N=100) | -0.3 ± 3.2 |
| Week 20 (N=97) | -0.1 ± 4.2 |
| Week 28 (N=91) | 0.2 ± 5.0 |
| Week 36 (N=87) | 0.4 ± 4.4 |
| Week 44 (N=82) | -0.3 ± 3.3 |
| Week 52 (N=77) | 0.6 ± 3.8 |
| Last vist (N=107) | 0.7 ± 4.5 |
The PARS is used to rate the severity of anxiety in children and adolescents, aged 6 to 17 years. The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score was the sum of items 2, 3, 5, 6, and 7. The total severity score ranged from 0 (no anxiety) to 25 (worst anxiety).
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | -0.3 ± 3.0 |
| Week 8 (N=105) | -0.3 ± 3.6 |
| Week 12 (N=104) | -0.5 ± 2.6 |
| Week 20 (N=100) | -0.4 ± 2.9 |
| Week 28 (N=91) | -0.2 ± 3.1 |
| Week 36 (N=88) | -0.7 ± 3.0 |
| Week 44 (N=82) | -0.5 ± 2.7 |
| Week 52 (N=77) | -0.4 ± 3.5 |
| Last vist (N=109) | -0.4 ± 3.5 |
The YGTSS is a semi-structured clinical interview which consists of a tic inventory, with 5 separate ratings to assess the number, intensity, frequency, complexity and interference of tics, plus an overall impairment/disability score. Ratings are made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics each, including number, frequency, intensity, complexity, and interference. Summation of these 10 scores (ie, 0-50) provides a TTS that was the secondary outcome measure in this trial. The YGTSS ranking of impairment, with a maximum of 50 points, is based on the impact of the tic disorder on areas of self-esteem, family life, social acceptance, and school scores. The total severity score ranged from 0 (no impairment) to 50 (worst impairment).
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 52 (N=77) | -8.6 ± 10.2 |
| Last visit (N=109) | -6.6 ± 10.9 |
The CGI is a 7-point Likert scale used in a multitude of clinical trials as a clinical global measure to assess the severity and change in disease symptomatology (ie, tics). The CGI was included as a secondary scale to provide a more complete assessment of clinical efficacy. To assess CGI-TS severity, the rater or investigator will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" However, the evaluation of illness will be limited to manifestations of Tourette's Disorder only. Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 52 (N=77) | 2.5 ± 1.6 |
| Last visit (N=109) | 2.5 ± 1.6 |
The final CGI-TS score was compared to the participant's baseline condition at the time of entry into the open-label study, rather than the CGI-TS baseline condition at the time participants enrolled into the preceding study. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 52 (N=77) | -0.9 ± 1.2 |
| Last visit (N=109) | -0.7 ± 1.3 |
The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) for motor and vocal tics, and an impairment ranking. The YGTSS TTS is the summation of the severity scores of motor and vocal tics (range of 0 \[no impairment\] to 50 \[maximum impairment\]). The total YGTSS score is the summation of the severity scores of motor and vocal tics and the ranking of impairment (total range of 0 \[no impairment\] to 100 \[maximum impairment\]).
| Units on a scale | Open-label Aripiprazole |
|---|---|
| Week 52 (N=77) | -18.0 ± 23.7 |
| Last visit (N=109) | -14.0 ± 24.3 |
Clinical response was defined as \> 25% improvement from Baseline to endpoint in YGTSS TTS or a CGI-TS change score of 1 (very much improved) or 2 (much improved) at endpoint.
| Percentage of participants with response | Open-label Aripiprazole |
|---|---|
| Week 4 (N=107) | 80.4 |
| Week 8 (N=105) | 81.9 |
| Week 12 (N=104) | 82.7 |
| Week 20 (N=100) | 75.0 |
| Week 28 (N=92) | 77.2 |
| Week 36 (N=88) | 75.0 |
| Week 44 (N=81) | 75.3 |
| Week 52 (N=77) | 67.5 |
The treatment discontinuation rate was calculated as the number of discontinued participants (ie, those withdrawn from the study without completing the Week 52 visit) divided by the number of all enrolled participants.
| Percentage of discontinued participants | Open-label Aripiprazole |
|---|---|
| Percentage of Participants With Treatment Discontinuation (Treatment Discontinuation Rate). | 31.8 |
Collected over Day 0 (Baseline) until Follow-up 30 Days (±3 days) after the last trial visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Aripiprazole | — | 4/110 (3.6%) | 84/110 (76.4%) |
| Event | Open-label Aripiprazole |
|---|---|
| Tourette's disorderCongenital, familial and genetic disorders | 1/110 |
| AppendicitisInfections and infestations | 1/110 |
| Infectious mononucleosisInfections and infestations | 1/110 |
| ConcussionInjury, poisoning and procedural complications | 1/110 |
| Intentional overdoseInjury, poisoning and procedural complications | 1/110 |
| Event | Open-label Aripiprazole |
|---|---|
| Weight increasedInvestigations | 26/110 |
| SomnolenceNervous system disorders | 13/110 |
| FatigueGeneral disorders | 11/110 |
| NasopharyngitisInfections and infestations | 11/110 |
| HeadacheNervous system disorders | 11/110 |
| VomitingGastrointestinal disorders | 10/110 |
| NauseaGastrointestinal disorders | 8/110 |
| PyrexiaGeneral disorders | 7/110 |
| Increased appetiteMetabolism and nutrition disorders | 6/110 |
| SedationNervous system disorders | 6/110 |
| Age, Continuous(Years) | Open-label Aripiprazole |
|---|---|
| Mean | 11.7 ± 2.9 |
| Sex: Female, Male(Participants) | Open-label Aripiprazole |
|---|---|
| Female | 24 |
| Male | 86 |
The record gives a start of Jan 2013, a primary completion of Aug 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →